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Abstract 
 
Purpose of review:  
The Epithelial-Mesenchymal Transition (EMT) and the generation of Cancer Stem Cells (CSCs) are 
two fundamental aspects contributing to tumor growth, acquisition of resistance to therapy, 
formation of metastases, and tumor relapse. Recent experimental data identifying the circuits 
regulating EMT and CSCs has driven the development of computational models capturing the 
dynamics of these circuits, and consequently various aspects of tumor progression.  
Recent findings:  
We review the contribution made by these models in a) recapitulating experimentally observed 
behavior, b) making experimentally testable predictions, and c) driving emerging notions in the 
field, including the emphasis on the aggressive potential of hybrid epithelial/mesenchymal (E/M) 
phenotype(s). We discuss dynamical and statistical models at intracellular and population level 
relating to dynamics of EMT and CSCs, and those focusing on interconnections between these two 
processes.  
Summary:  
These models highlight the insights gained via mathematical modeling approaches, and 
emphasizes that the connections between hybrid E/M phenotype(s) and stemness can be 
explained by analyzing underlying regulatory circuits. Such experimentally curated models have 
the potential of serving as platforms for better therapeutic design strategies. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Metastasis and tumor relapse are insuperable clinical challenges that claim most cancer-related 
deaths [1]. The metastatic cascade has extremely high rates of attrition, because of the multi-step 
and challenging sequence of events leading to a secondary tumor. These steps include the 
detachment of cancer cells from their home organ, their circulation in the bloodstream, and 
eventually their colonization of a foreign environment, all while escaping attack by the immune 
system and other clinical interventions. 
 
A first step in the metastatic cascade is a phenotypic switch called Epithelial-to-Mesenchymal 
Transition (EMT). Cancer cells in a solid tumor tissue often undergo EMT, characterized by the loss 
of cell-cell adhesion and acquisition of migratory and invasive traits [2]. Disseminated cells travel 
through the bloodstream and colonize a distant organ, giving rise to macrometastases [2, 3]. EMT 
is not necessarily a cell-autonomous and binary process. Cells can attain one or more 
intermediate, or hybrid, epithelial/mesenchymal (E/M) state(s) and can involve their neighbors to 
form more aggressive clusters of circulating tumor cells (CTCs) - the main drivers of metastases [4–
6]. EMT is regulated at multiple levels – transcriptional, translational, post-translational and 
epigenetic – by many context-specific factors and the tumor microenvironment. Some common 
traits of EMT include transcriptional repression of E-Cadherin that mediates cell-cell junctions and 
adhesion, and activation of one or more EMT-inducing transcription factors (EMT-TFs) such as 
SNAI1, SNAI2, ZEB1, ZEB1, TWIST1 that induce can cell scattering, motility, and invasion [2].  
 
To colonize a secondary tumor site, the disseminated tumor cells need to give rise to different cell 
types that constitute a tumor – a trait typical of cancer stem cells (CSCs). Cells with such stem-like 
properties are also typically resistant to various clinical treatments, and are often implicated in 
tumor relapse. The conventional, so-called ‘CSC hypothesis’ envisions a small fraction of CSCs that 
can both self-renew (symmetric division) and generate differentiated cells (asymmetric division) 
[7, 8]. This hypothesis implies a hierarchical lineage of tumor cells similar to stem cell hierarchy in 
normal tissues, such that CSCs that differentiate irreversibly lose their stem-like properties [9]. 
Recent studies, however, have emphasized that stemness can be a dynamic cell state that can be 
acquired or lost [10–13]. In other words, some differentiated tumor cells can dedifferentiate and 
regain stemness via epigenetic and/or environmental factors such as abnormal cancer metabolism 
and EMT.  
 
The interconnection between EMT and CSCs was first postulated by Brabletz et al. [14] in 2005 as 
‘migrating cancer stem cell’ by suggesting that the concepts of EMT and CSCs, considered 
independent of one another, were not sufficient to explain various traits of cancer progression. 
Afterwards, experimental evidence accumulated suggesting that stemness can be gained during 
EMT [2, 5, 15–19]. Recent experiments have shown that cells in intermediate E/M states possess a 
higher metastatic potential as compared to the cells that have undergone a complete EMT. 
Moreover, cells in hybrid E/M phenotype have been suggested to be drug-resistant [20, 21]. Put 
together, these observations emphasize the clinical implications of hybrid E/M phenotypes [5, 22, 
23].  
 
Recent studies have made significant progress in identifying the molecular networks regulating 
EMT, CSCs, and their interconnections [24]. These networks are formidably complex, and capable 
to give rise to emergent non-linear behavior. Identification of these networks has driven a surge in 
deciphering their underlying principles from a dynamical systems perspective. This approach has 
involved developing many computational models to capture the dynamics of these transitions. 
These models may deal with intracellular and intercellular circuits, or may offer a population level 
description without considering the detailed dynamics of signaling networks. Here, we review 
both of these types of models. First, we review a set of models that attempt to characterize the 
possible set of states for cells undergoing EMT and their possible relevance to tumor progression 
and metastasis. Second, we review a set of models that consider the population structure of a 
tumor and its implications for drug resistance. Finally, we discuss models that aim at gaining a 
comprehensive understanding of the connection between these two crucial axes of cancer 
progression. 
 
 
Mathematical models of EMT 
 
Computational models developed for EMT can be categorized broadly into two classes: 
mechanism-based models and data-based models. While the first class of models adopts a 
‘bottom-up’ approach and focus on elucidating the properties of molecular networks identified 
experimentally, the latter adopts a ‘top-down’ approach starting with high-dimensional data and 
aims to reverse engineer the networks, and/or trace the trajectories of these transitions using 
statistical methods. 
 
 
1. Decoding the dynamics of cellular transitions: Mechanism-based models of EMT 
 
The first set of mechanism-based models for EMT regulation – developed independently by two 
groups – focused on a small set of nodes, and captured the dynamical features emerging from the 
interconnections among those nodes (Fig. 1A, left). These models included the EMT-suppressing 
microRNA families miR-34, miR-200 and the families of EMT-TFs ZEB and SNAIL [25, 26]. Both 
models predicted that this network can be tristable, and could give rise to a hybrid epithelial/ 
mesenchymal (E/M) phenotype, in addition to epithelial and mesenchymal phenotypes (Fig. 1A, 
right) [25, 26]. These models also suggested that more than one phenotype can be accessible to a 
cell due to the underlying multistability, hence giving rise to sub-populations of epithelial, hybrid 
E/M and mesenchymal cells in a genetically identical population. This phenomenon was observed 
and later characterized in detail in multiple cancer cell lines [5, 27–29]. Due to different modeling 
approaches, however, these models differed on the dynamics of attaining this hybrid E/M 
phenotype. Experimental support for both these models has been observed [27, 30], highlighting 
the heterogeneity and multiplicity of hybrid E/M phenotype(s) present in different cell lines.  
 
Further follow-up work has identified several intracellular phenotypic stability factors (PSFs) that 
can stabilize a hybrid E/M phenotype, including OVOL2, GRHL2, Np63α and NRF2 [31–35]. Their 
role as PSFs have also been validated experimentally in vitro and in vivo [32, 34–36]. Moreover, 
higher levels of these PSFs were observed to correlate with worse patient survival, emphasizing 
the clinical implications of hybrid E/M phenotype(s) [4, 22]. Among those, NRF2 has been 
specifically proposed to be maximally expressed in hybrid E/M phenotype(s) [35]. In addition, 
different energy landscape approaches have been also developed for the aforementioned EMT 
circuit [37] as well as for related larger gene regulatory circuits [38]. This strategy allows to 
compute the transition rates between multiple cell states, and thus predict the relative abundance 
of different phenotypes (epithelial, mesenchymal, and hybrid E/M) in an isogenic population. 
 
EMT can be also induced by biochemical signals coming from neighboring cells. Boareto et al. [39] 
elucidated the connection between EMT and the Notch signaling pathway, a cell-cell, contact-
based, evolutionary conserved signaling mechanism that is also implicated in angiogenesis and 
therapy resistance. The model predicted that Notch-Jagged signaling among cells, but not Notch-
Delta signaling, can foster the formation of clusters of hybrid E/M cells by promoting a similar 
hybrid E/M phenotype in neighboring cells [39]. Consistently, gene expression analysis highlighted 
higher levels of Jagged in CTC clusters of patients as compared to single CTCs [33]. Thus, a hybrid 
E/M phenotype can be stabilized not only by intracellular PSFs directly coupled to the EMT core 
circuit, but also via cell-cell signaling. As another example, Bocci et al. [40] predicted that Numb – 
an inhibitor of Notch signaling – can also stabilize a hybrid E/M phenotype; this prediction was 
validated experimentally in multiple independent studies [40, 41]. 
 
As the network grows in size (such as going from Fig 1A to Fig. 1B), identifying kinetic parameters 
becomes more and more challenging. Computational models that have focused on such larger 
networks have typically been simulated using Boolean modeling approaches, where the state of 
gene expression is either On (active) or Off (inactive). Boolean models do not consider any kinetic 
parameters. Cohen et al. [42] developed a Boolean network to evaluate the combinatorial effect 
of different mutations on EMT and metastatic potential using transcriptome data from TGF-𝛽-
induced EMT. Similarly, Steinway et al. [43] constructed a circuit for TGF-𝛽-induced EMT using 
data from hepatocellular carcinoma (HCC). Their model predicted the activation of several 
pathways during EMT such as Sonic Hedgehog and Wnt. Following up, the authors showed that 
certain perturbations could give rise to one or more hybrid E/M states, and identified possible 
targets to inhibit TGF-𝛽-driven EMT [44]. Recently, Font-Clos et al. [45] constructed Boolean 
model for a gene regulatory network that describes both EMT and its reverse, Mesenchymal-to-
Epithelial Transition (MET). An energy landscape approach showed two main attractors, or stable 
states, corresponding to epithelial and mesenchymal phenotypes, and multiple local minima, or 
relatively less stable states, corresponding to multiple hybrid E/M phenotypes (Fig. 1C). The 
authors further mapped RNA-seq data from both lung adenocarcinoma and embryonic 
differentiation during EMT/MET and compared it to the predicted phenotypic expression profiles, 
hence validating the existence of multiple different intermediate E/M states.  
 
In an attempt to combine the advantages of both continuous small-scale models and Boolean 
large-scale models, Huang et al. [46] devised an algorithm - Random Circuit Perturbation (RACIPE) 
- where the expression levels of genes are continuous, but the parameters for all regulatory links 
are randomly chosen within a biologically-relevant range. RACIPE generates an ensemble of 
mathematical models, each with a different set of parameters, and identifies the robust dynamical 
states emerging from a given network topology. Applying RACIPE to an EMT circuit composed of 9 
microRNAs and 13 TFs (Fig. 1B) highlighted two different hybrid E/M states [46] that could be 
stabilized further by stochasticity or noise [47]. 
 
 
2. Reconstructing EMT plasticity from experiments: data-driven approaches to EMT 
 
Recent experimental techniques are capable of generating large and high-throughout (‘omics’ 
level) data. This deluge has driven a class of data-driven, or ‘top-down’, models, which employ a 
variety of statistical tools to reconstruct correlations among genes and develop expression 
signatures of different EMT phenotypes. 
 
 
Figure 1. Mathematical models that characterize the landscape of cellular plasticity mediated via 
EMT and CSCs. (A) Left: a gene regulatory circuit for EMT adapted from Hong et al. [34]. Right: a 
bifurcation diagram of ZEB mRNA as a function of EMT-TF SNAIL adapted from Lu et al. [25] shows 
three stable phenotypes (i.e. continuous black curves) corresponding to epithelial (low ZEB), hybrid E/M 
(intermediate ZEB) and mesenchymal (high ZEB).  (B) An extended EMT regulatory circuit adapted from 
Huang et al. [46]. (C) The energy landscape of a large EMT regulatory circuit adapted from Font-Clos et 
al. [45] shows two main minima (purple and green projections) corresponding to epithelial and 
mesenchymal phenotypes, respectively. Additionally, many local energy minima en route to EMT 
correspond to intermediate E/M states. PCA0 and PCA1 are the first two components of the Principal 
Component Analysis of the circuit. (D) Chemotherapy increases the population of chemo-resistant 
cancer cells (CD44hiCD24hi) by increasing the conversion rate from low-resistance CD44low cell 
population. Top: circuit schematic; Bottom: Temporal dynamics of cancer cell subpopulations pre- and 
post-treatment adapted from Goldman et al. [67]. (E) Left: a core gene regulatory circuit including 
regulation of EMT via the miR-200/ZEB axis and stemness via the LIN28/let-7 axis adapted from Jolly et 
al. [12]. The parameters 𝛼#, 𝛼$ represent the strength in the regulation of the stemness circuit by the 
EMT circuit (𝛼#) and the EMT circuit by the stemness circuit (𝛼$). Right: varying 𝛼# and 𝛼$ shifts the 
‘stemness window’ along the EMT axis adapted from Jolly et al. [12].  (F) The EMT score of different 
cancer stem cell lines adapted from Bocci et al. [13] shows the spread of CSC properties along the EMT 
spectrum. The score classifies cells as epithelial (score<0.5), hybrid E/M (0.5<score<1.5) or 
mesenchymal (score>1.5). Each row depicts a different CSC line, and each dot depicts a different 
biological replicate. 
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For example, Zadran et al. [48] analyzed the temporal mRNA data of A549 lung cancer cells 
treated with TGFβ, and identified an intermediate EMT state with a metabolic state characterized 
by increased cytosolic ATP levels [48]. Further, Chang et al. [49] analyzed the time course data of 
TGF-𝛽-driven EMT for A549 cells and identified three master TFs for a partial EMT state - ETS2, 
HNF4A and JUNB [49]. These regulators correlate with a worse clinical outcome and their 
knockdown can prevent TGFβ-driven EMT [49], reminiscent of observations made for PSFs. 
 
Besides, two different groups developed methods to analyze gene expression data of a certain cell 
line or tumor cell and calculate an ‘EMT score’ to quantify the positioning of these cells along the 
EMT spectrum. The algorithm developed by Tan et al. uses entire transcriptomic data for a given 
sample [50], while that developed by George et al. considers a few E and M markers (such as E-
Cadherin, Vimentin etc.) as well as PSFs of hybrid E/M phenotypes (OVOL, GRHL2 etc.) [23].  
 
Data-driven models do not necessarily rely on omics-level data; they can also use morphological 
data. For instance, Mandal et al. [51] proposed a phenomenological approach to elucidate 
intermediate EMT states based on cell microscopy during EMT, and found 3 intermediate states 
with different morphological attributes [51]. A more rigorous analysis was proposed by Leggett et 
al. [52] that relies on single cell microscopy to classify cells as epithelial or mesenchymal with high 
precision during TGF-β-driven EMT [52]. Even further, Zhang et al. [53] classified the morphology 
and motility of migrating breast cancer cells using machine learning algorithms such as Artificial 
Neural Networks (ANN) and Random Decision Forest (RDF) to analyze single-cell microfluidic 
microscopy images [53].  
 
As the connections between molecular and morphological traits of EMT continue to be explored in 
detail [54], a synergistic crosstalk among the computational models described above and their 
integration with experimental data can provide novel and crucial insights into the dynamics of 
EMT. 
 
 
Mathematical models of CSCs 
 
 
1. Modeling the CSC fraction during tumor progression 
 
An important direction where mathematical approaches have offered significant insights into the 
CSC dynamics and its relationship with tumor progression is a set of population dynamics models 
that aim at understanding the temporal dynamics and the mechanisms regulating the CSC fraction 
(the fraction of cells with stem cell properties in a tumor) [55, 56]. Dhawan et al. [57] considered 
two compartments, the CSC-like cells and the non CSC-like cells, to elucidate the increased 
plasticity observed in human mammary epithelial cells under hypoxia. In their model, individual 
cells can both differentiate (from CSC to non-CSC) and dedifferentiate (from non-CSC to CSC). 
Integrating their model with gene expression analysis, the authors showed that hypoxia generates 
a shift toward a more CSC-like population and increases EMT features [57].  
 
The role of cell dedifferentiation to a stem-like state has been also investigated by Jilkine et al. 
[58] via a hybrid model that describes the development of the differentiated cell population in a 
deterministic manner, but considers the stochastic accumulation of mutations to better describe 
the small CSC population. The authors concluded that dedifferentiation to a stem-like state can 
speed up tumor progression by enlarging the CSC population [58].  
 
Among the different possible mechanism for dedifferentiation, metabolic reprogramming is 
especially frequent in the context of cancer [59]. Liu et al. [60] devised a probabilistic framework 
to specifically investigate metabolic reprogramming that converts somatic cells into pluripotent 
stem cells. Insights gained from such analysis may be useful in understanding metabolic aspects of 
tumor cell dedifferentiation, given that different subsets of CSCs may have different metabolic 
vulnerabilities [61]. 
 
Another set of models have aimed to explain how a fraction of CSCs is maintained in a tumor. 
Zhou et al. [62] developed a population model of tumor growth that integrates the differential 
growth rate of CSCs and differentiated cells, as well as transitions among cell phenotypes. In 
particular, switching between phenotypes maintains a fixed ratio of cell sub-populations [62]. 
Extending this idea, Wang et al. [63] proposed a population model that combines hierarchical 
organization (irreversible loss of stem traits upon differentiation) and stochastic switching 
(stemness can be gained by switching to a stem-like state). In this model, CSCs can (a) self-renew 
(symmetric division in two CSCs), (b) differentiate (symmetric division into two non-stem cells) and 
(c) asymmetrically divide into a CSC and a daughter differentiated cell. Additionally, differentiated 
cells can proliferate (symmetric division) but also switch to the progenitor CSC state [63]. The 
combination of hierarchical and stochastic processes can reproduce the CSC/differentiated cell 
fraction observed in a human colon cancer cell population [63]. A similar idea has been proposed 
by Zhou et al. [64] to show that back and forth transitions between stem-like and non-stem states 
is crucial to establish an equilibrium cell fraction of CSCs [64]. 
 
A different approach to model CSC-driven tumor progression was proposed by Poleszczuk et al. 
[65]. They proposed an agent-based model where CSCs can gain migratory traits by stochastic 
mutations. Such approach enables to simulate the spatiotemporal dynamics of the cancer cell 
population and investigates the cell heterogeneity that arises during tumor development due to 
mutations. In this model, CSC can divide symmetrically or asymmetrically, and also have a 
migration potential that translates into discrete movements on a two-dimensional lattice [65], 
reminiscent of the idea of ‘migrating cancer stem cell’ proposed by Brabletz [14].  
 
 
2. CSC, tumor progression and therapy: from modeling to the clinic 
 
A subset of recent models have focused their attention toward identifying optimal therapy 
schedules for cancer treatment [66]. In this context, CSCs are considered as important target 
because they are resistant to therapy, and can therefore drive tumor progression and relapse. For 
instance, the model developed by Dhawan et al. [57] (discussed in the previous section) can be 
generalized to the context of drug tolerance by introducing one or more additional cell sub-
populations that can resist different treatments [67]. Specifically, the authors show by integrating 
in vivo experiments and mathematical modeling that chemotherapy can change the rates of 
conversions among different cell phenotypes and promote a chemotherapy-tolerant state (Fig. 
1D) [67]. 
 
A more data-driven approach aims to correlate the CSC population with tumor progression and 
response to therapy. For instance, Werner et al. [68] proposed a computational method to 
quantify the fraction of tumor-initiating cells (i.e. CSCs) by analyzing the tumor’s macroscopic 
growth rate as a function of time. This patient-specific method can be applied to many types of 
tumors, and provides an estimate of the CSC fraction to rationalize the optimal therapy in a clinical 
setting [68]. Zhou et al. [69] applied a statistical approach to compute the transition rate between 
CSC and differentiated cells in colon cancer cells and showed phenotypic plasticity with back and 
forth transitions [69]. Furthermore, Yu et al. [70] gathered the differential response of CSCs and 
differentiated cells to radiotherapy for different tumor types including glioblastoma, lung, 
prostate, and breast cancer, and fitted this tumor-specific information with a stochastic 
mathematical model to explain the different inter-tumor responses to radiation therapy [70].  
 
Not all models of cancer cell-therapy interplay need to employ a population approach. Instead, 
Chen et al. [71] used an energy landscape approach to investigate the transitions of breast cancer 
cells which are sensitive, hypersensitive or insensitive to hormone therapy regulated by the ER𝛼 
signaling network. The authors implemented different treatment strategies including sequential 
treatment (multiple drugs) and intermittent treatment (alternation of treatment and ‘drug 
holiday’ periods) [71]. The effects of continuous vs. intermittent treatments was also explored in 
the context of prostate cancer, where a small-scale model predicted that cells could oscillate 
between a therapy-sensitive and a therapy-resistant phenotype [72]. The authors further modeled 
different hormonal treatments for prostate cancer that were predicted to synchronize oscillations 
among different cells, thus restricting the heterogeneity in the cell population [73].  
 
As discussed above, most models related to CSCs have largely focused on identifying the causes 
underlying varying fractions of tumor population that can behave as CSCs [74]. Thus, there is much 
room for progress in constructing mechanistic models for CSC-driven tumor progression and the 
emergence of drug-resistant phenotypes. In this direction, Nazari et al. [75] recently proposed a 
mathematical model for the role of inflammatory cytokines in mediating CSC-driven tumor 
growth. This model couples the ligand-receptor interaction at the molecular scale with CSC self-
renewal and proliferation at the cellular level [75], and could reproduce the observed decrease in 
tumor volume in mouse models with knockdown of IL-6R, an inflammatory cytokine. 
 
Towards an integrated understanding of EMT and CSC 
 
Aside from the separate models for EMT and CSC dynamics as discussed above, multiple 
computational models have investigated the connection between EMT and CSC. Turner et al. [76] 
interrogated the connection between EMT and CSC through a phenomenological, population 
model with two possible scenarios where EMT enriches the CSC population. First, cells can 
dedifferentiate back to a CSC state while undergoing EMT. Secondly, EMT increases the probability 
of symmetric, self-renewal division of cells that are already stem-like [76]. The authors used the 
model to fit the experimental data on CSC fraction and mammosphere expansion, indicating that 
both processes may play an important role in supporting cancer progression [76]. Later, Gupta et 
al. [77] showed that breast cancer cells can exist in different sub-populations with varying 
functional attributes: luminal, basal and stem-like. They demonstrated that the overall population, 
when perturbed, re-establishes a fixed fraction of the three cell phenotypes. This robustness could 
be explained by a population model where cells can undergo stochastic phenotypic transitions 
between the three different states [77]. Moreover, the stem-like cell line SUM 149 has been 
shown to exhibit the traits of a hybrid E/M phenotype, hence suggesting a possible correlation 
between a partial EMT state and stemness [33]. 
 
The multi-scale model proposed by Sfakianakis et al. [78], instead, focuses on resolving the spatial 
structure of a cancer cell population. This phenomenological model couples the aspects of CSC and 
EMT to describe the invasion of extracellular matrix by tumor cells. In this framework, EMT is 
modeled as a binary switch between an epithelial-like and a mesenchymal-like phenotype that is 
driven by growth factors. Therefore, this model couples EMT at the individual cell scale and the 
population dynamics and growth of the tumor mass at the multi-cell scale. Note, however, that 
the models discussed so far proposed mechanisms for CSC-driven tumor progression and 
maintenance of the CSC fraction, but did not provide a molecular rationale for the acquisition of 
CSC traits. 
 
Li and Wang [38] reconstructed a core gene regulatory circuit with relevant players determining 
CSC properties such as miR-145 and OCT4, and core regulators of EMT - miR-200 and ZEB. The 
authors applied an energy landscape approach to predict the co-existence of multiple cellular 
phenotypes. In their model, a cell can either assume a ‘normal’ state or a ‘cancer’ state, both of 
which could or could not exhibit stem-like traits. Thus, a total of four possible cell phenotypes are 
available – normal, normal stem-like, cancer, and cancer stem-like [38]. In this framework, p53 
represents a degree of cancerization and ZEB represents a degree of stemness. Notably, both the 
predicted ‘normal stem cell’ state and the ‘CSC’ state highly express ZEB, hence implicitly 
suggesting that stemness is gained along with EMT [38].  
 
Finally, the models developed by Jolly and colleagues explicitly proposed a mechanism-based 
rationale to elucidate the connection between EMT and CSC: the stemness circuit  comprising 
LIN28, let-7, and OCT4 is connected to the EMT circuit already discussed by Lu et al. [25] (Fig. 1E, 
left). The CSC phenotype was defined as a state with intermediate levels of OCT4 that have been 
shown experimentally to correlate with stem-like traits [79, 80].  These models proposed that a 
CSC phenotype is highly correlated with a hybrid E/M phenotype [81], but intracellular factors 
such as OVOL [12] or cell-cell communication via Notch signaling [13] could move the predicted 
‘stemness window’ toward the epithelial or mesenchymal ends of the EMT spectrum (Fig. 1E, 
right). Experimental evidence for this dynamic ‘stemness window’ concept was provided by Bocci 
et al. [13] by computing the ‘EMT score’ [23] of different human CSC lines using publicly available  
datasets . This analysis showed that CSC traits can be scattered along the EMT spectrum based on 
context-specific activation of signaling pathways, therefore resulting in epithelial, hybrid E/M and 
mesenchymal CSC (Fig. 1F) [13]. Furthermore, this model proposed a strong overlap between a 
hybrid E/M phenotype, CSC properties and Notch-Jagged signaling [13], a pathway implicated in 
both drug resistance and in clusters of CTCs, the key drivers of metastasis [33]. Consistently, 
knockdown of Jagged was shown to restrict the growth of tumor emboli in SUM149 inflammatory 
breast cancer cells [82]. Given the role of Notch signaling in pattern formation in multiple contexts 
[83, 84], Notch signaling coupled with EMT circuitry may underlie the spatial segregation of 
different subsets of cells with stem-like traits, as observed experimentally in a breast cancer tissue 
[85]. Secretion of a diffusive EMT-inducing signal at the tumor-stroma interface (such as TGF-𝛽), 
along with cell-cell signaling through Notch, was shown to give rise to mesenchymal CSCs at the 
invasive edge of the tumor and a population of hybrid epithelial/mesenchymal (E/M) CSCs in the 
tumor interior [82]. The idea that cell-cell signaling and the microenvironment can shape the 
spatial distribution of a cell population has been examined in different biological contexts, such as 
bacterial colonies [86, 87] or eukaryotic chemotaxis [88, 89], but remains largely unexplored in 
cancer biology, and thus demands further attention.  
 
 
Conclusion 
 
EMT and CSC represent two crucial biological axes that bolster tumor progression, metastasis and 
tumor relapse [2, 4]. While the molecular details of multiple steps of tumor development continue 
to be identified, it is largely accepted that EMT often plays a crucial role in regulating epigenetic, 
morphological and functional cell properties during tumor progression and metastasis formation 
[2, 4]. Similarly, it is well accepted that the acquisition of stem-like properties potentiates tumor 
maturation and enhances resistance to various treatments, driving tumor relapse. Only recently, 
we have been gaining insights into how, when and where these two dynamic processes can 
influence one another (Fig. 2). In this context, mathematical modeling has proven itself as a potent 
tool to interpret existing data and formulate new predictions that can be tested experimentally. 
 
In the context of EMT, mechanism-based computational models have suggested that cells 
undergoing EMT can stably acquire intermediate cell states enabling hybrid phenotypes with 
mixed epithelial (E) and mesenchymal (M) characters, as opposed to a binary E-M switch scenario 
[2, 4]. Novel in vivo and in vitro analysis recently highlighted the existence of such hybrid states 
that coexpress E and M markers and often possess mixed morphological traits of cell-cell adhesion 
and motility [18, 19], and have highlighted their enhanced metastatic potential [90]. The next 
crucial steps will include a more comprehensive attempt to integrate data-based models, 
mechanism-based models, and time-course and single-cell experimental data, to formulate a more 
quantitative characterization of these malignant hybrid E/M state(s). 
 
In the context of CSC, one set of models considers the dynamics of a CSC population employing 
the tools of population dynamics and agent-based modeling. Such class of models can provide 
predictions about CSC fraction or population dynamics under perturbations, hence potentially 
providing strategies for containing CSC-driven tumor progression. Additionally, coupling 
mathematical modeling with clinical data of therapy response enables predictive tools that can 
shed light on the CSC-therapy interplay. Such models can provide information on, among others, 
adaptive response, differential drug sensitivity, or phenotypic plasticity in a cancer cell population. 
 
Recent experimental observations have led to a class of models that can offer insights into the 
coupling between EMT in cancer cells and the acquisition of stem-like properties. A first set of 
models relates phenomenologically the acquisition of stem traits with the EMT process, hence 
explaining how CSC-EMT interaction can support tumor progression and maintain a certain 
fraction of different cell phenotypes. Moreover, a second class of models investigates the coupling 
between EMT and CSC at the level of gene regulatory networks, showing a correlation between 
the cell phenotypes enabled by an EMT regulatory circuit and the stemness regulatory circuit. A 
common feature across these models is envisioning the acquisition of stemness as a dynamical 
process correlated with EMT [12, 13, 38]. Recent mathematical modeling and experiments have 
suggested a correlation among hybrid E/M states and stem cell properties [5, 12, 13, 18, 19]. CSC 
traits, however, are not exclusively observed in intermediate states, and the crosstalk between 
tumor, micro-environment and therapies is likely to play a major role in modulating the plasticity 
properties of cancer cells (Fig. 2), as shown by recent experiments highlighting subsets of CSCs in 
multiple cancer types [20, 85]. 
 
Considered together, these computational models developed for EMT, CSC, or their inter-
connections have contributed not only in deciphering the mechanisms underlying specific 
experimental observations, but also have driven the next set of experiments by generating 
testable predictions. Such bidirectional crosstalk between theory and experiments can significantly 
accelerate our goal of understanding and consequently targeting these processes for therapeutic 
benefit. 
 
 
 
Figure 2. Interconnections between EMT and CSC axes. The spectrum of EMT states can range from 
epithelial (E) to mesenchymal (M) phenotypes, with a variable number of partial E/M states (x-axis). 
Both cancer stem cells and differentiated cancer cells can assume different states depending on genetic 
and epigenetic factors (y-axis). Horizontal and vertical transitions represent independent EMT and stem 
processes, respectively. However, transitions are possible where both the EMT and stem states change, 
or correlated transition. The interconnection among EMT and CSC states and the transitions enabled 
between them depend on context-specific factors including, among others, intra-cellular signaling and 
mutations, cell-cell and cell-environment signaling. 
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